| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vivo |
This study assessed the efficacy of pyrimethamine and sodium sulfadiazine in treating mice infected with various atypical Toxoplasma gondii during an acute infection. A total of seven strains of Toxoplasma gondii were injected into Swiss mice. Treatment for the infected mice involved giving them 10-640 mg/kg of sodium sulfadiazine, 3-200 mg/kg of pyrimethamine, or a less potent combination of the two medications every day. The relationship between genotype and sensitivity to sodium and/or pyrimethamine was assessed using descriptive analysis. Treatment with salt or pyrimethamine decreased the sensitivity of the TgCTBr4 and TgCTBr17 strains (genotype 108). Similar sensitivity to PYR was seen in TgCTBr1 and TgCTBr25 strains (genotype 206), but not in response to salt treatment. The only strain that responds well to treatment with both medications is the TgCTBr9 strain (genotype 11) [1].
|
|---|---|
| References |
|
| Additional Infomation |
Sulfadiazine Sodium is a sodium salt form of sulfadiazine, an intermediate-acting bacteriostatic, synthetic sulfanilamide derivative.
See also: Sulfadiazine (has active moiety); Pyrimethamine; Sulfadiazine Sodium (component of); Sulfadiazine Sodium; Trimethoprim (component of). |
| Molecular Formula |
C10H9N4NAO2S
|
|---|---|
| Molecular Weight |
272.2588
|
| Exact Mass |
272.034
|
| CAS # |
547-32-0
|
| Related CAS # |
Sulfadiazine;68-35-9;Sulfadiazine-d4;1020719-78-1
|
| PubChem CID |
15899898
|
| Appearance |
White to off-white solid powder
|
| Density |
1.496g/cm3
|
| Boiling Point |
512.6ºC at 760 mmHg
|
| Flash Point |
263.8ºC
|
| LogP |
2.38
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
332
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JLDCNMJPBBKAHH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H9N4O2S.Na/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
|
| Chemical Name |
sodium;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~459.12 mM)
H2O : ~100 mg/mL (~367.30 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6730 mL | 18.3648 mL | 36.7296 mL | |
| 5 mM | 0.7346 mL | 3.6730 mL | 7.3459 mL | |
| 10 mM | 0.3673 mL | 1.8365 mL | 3.6730 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
